Health Information

Medroxyprogesterone

Drug Information

Medroxyprogesterone is a semisynthetic compound that differs in structure from the naturally occurring human hormone Reference progesterone. It is added to estrogen replacement therapy to prevent uterine cancer caused by unopposed estrogen. It is also used to treat absence of menstrual bleeding (amenorrhea) and abnormal menstrual bleeding. Medroxyprogesterone is available alone and in a combination product. An injection product is used for contraception.

Common brand names:

Depo-Provera, Provera, Amen, Cycrin

Summary of Interactions with Vitamins, Herbs, & Foods

Reference What Are Nutrient Interactions

Types of interactions: Beneficial Adverse Check

Replenish Depleted Nutrients

none

Reduce Side Effects

none

Support Medicine

none

Reduces Effectiveness

none

Potential Negative Interaction

none

Explanation Required

Reference Folic Acid

In a one-year study of predominantly malnourished women in India and Thailand, medroxyprogesterone used for contraception was associated with increased blood levels of vitamin A and folic acid.¹ The clinical meaning of these changes remains unclear.
Reference Magnesium

In a group of 37 postmenopausal women treated with conjugated estrogens and medroxyprogesterone for 12 months, urinary zinc and magnesium loss was reduced in those women who began the study with signs of Reference osteoporosis and elevated zinc and magnesium excretion.² The clinical significance of this interaction remains unclear.
Reference Vitamin A

In a one-year study of predominantly malnourished women in India and Thailand, medroxyprogesterone used for contraception was associated with increased blood levels of vitamin A and folic acid.³ The clinical meaning of these changes remains unclear.
Reference Vitamin D

In a study of postmenopausal women, treatment with estrogen alone increased vitamin D blood levels, whereas estrogen plus medroxyprogesterone lowered vitamin D back to the level seen without estrogen use.⁴ This outcome might suggest that medroxyprogesterone interferes with beneficial effects estrogen may have on vitamin D metabolism and vitamin D supplementation would be called for. However, some research has not found the addition of vitamin D to estrogen/progestin combinations to be helpful.⁵ Therefore, while many doctors recommend 400 IU vitamin D to women taking estrogen/progestin combination hormone products, the efficacy of such supplementation has not been proven.
Reference Zinc

In a group of 37 postmenopausal women treated with conjugated estrogens and medroxyprogesterone for 12 months, urinary zinc and magnesium loss was reduced in those women who began the study with signs of Reference osteoporosis and elevated zinc and magnesium excretion.⁶ The clinical significance of this interaction remains unclear.

The Drug-Nutrient Interactions table may not include every possible interaction. Taking medicines with meals, on an empty stomach, or with alcohol may influence their effects. For details, refer to the manufacturers’ package information as these are not covered in this table. If you take medications, always discuss the potential risks and benefits of adding a new supplement with your doctor or pharmacist.

References

1. Joshi UM, Virkar KD, Amatayakul K, et al. Impact of hormonal contraceptives vis-a-vis non-hormonal factors on the vitamin status of malnourished women in India and Thailand. World Health Organization: Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Oral Contraceptives. Hum Nutr Clin Nutr 1986;40:205–20.

2. Herzberg M, Lusky A, Blonder J, Frenkel. The effect of estrogen replacement therapy on zinc in serum and urine. Obstet Gynecol 1996;87:1035–40.

3. Joshi UM, Virkar KD, Amatayakul K, et al. Impact of hormonal contraceptives vis-a-vis non-hormonal factors on the vitamin status of malnourished women in India and Thailand. World Health Organization: Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Oral Contraceptives. Hum Nutr Clin Nutr 1986;40:205–20.

4. Bikle DD, Halloran BP, Harris ST, Portale AA. Progestin antagonism of estrogen stimulated 1,25-dihydroxyvitamin D levels. J Clin Endocrinol Metab 1992;75:519–23.

5. Komulainen M, Tuppurainen MT, Kroger H, et al. Vitamin D and HRT: no benefit additional to that of HRT alone in prevention of bone loss in early postmenopausal women. A 2.5-year randomized placebo-controlled study. Osteoporosis Int 1997;7:126–32.

6. Herzberg M, Lusky A, Blonder J, Frenkel. The effect of estrogen replacement therapy on zinc in serum and urine. Obstet Gynecol 1996;87:1035–40.

Last Review: 11-07-2012

Please read the Reference disclaimer about the limitations of the information provided here. Do NOT rely solely on the information in this article. The Aisle7 knowledgebase does not contain every possible interaction.

Reference Learn more about Aisle7, the company.

The information presented in Aisle7 is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires June 2013.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Reference Terms of Use. Reference How this information was developed to help you make better health decisions.